96-Well Chromatin Immunoprecipitation (ChIP) Assay
Porvair Sciences has announced an application note describing the excellent results achievable from a new 96-well format version of its ChromaTrap chromatin immunoprecipitation (ChIP) assay technology.
Developments in the field of epigenetics are rapidly expanding as researchers elucidate the principles governing gene regulation through the in vivo dynamic binding of proteins to DNA. Key to this is the need to analyse large numbers of high and low abundant regulatory mechanisms to systematically map protein-DNA interactions following pathogen/disease stimulus.
Chromatin immunoprecipitation (ChIP) assays are used to study these associations and have been historically limited to large sample numbers, onerous washing steps resulting in valuable sample losses and low signal to noise coupled with poor reproducibility. This new application note details the use of Chromatrap 96 Pro-A, a 96-well plate, each well of which contains a solid phase rigid porous polymer, BioVyon, to which Protein A is chemically bound, allowing up to 96 ChIP assays to be run in parallel on the same plate.
To determine ease of use, experimental design flexibility and reproducibility in screening multiple epigenetic targets with Chromatrap 96, the binding efficiency and occupancy of common epigenetic marks (H3, H4, H3K4me3 and RNA pol II) on three gene targets of interest (GAPDH, beta-globin, and PABPC1) in three human chromatin samples (HepG2, HeLa and K562) were performed simultaneously on the 96-well plate and analysed using qPCR. The application note describes in detail the analytical methodology, data interpretation and statistical analysis, as well as the benefits of using the new Chromatrap 96 high throughput ChIP assay plate, which include multiple target screening, flexible experimental design, robust reproducibility, high data quality and automated liquid handling potential.
To download a copy of this new application note, click here.
For further information or to discuss your application with technical product specialists please contact Porvair Sciences on +44 1372 824 290 / [email protected]
Related News
-
News Federal judge blocks Colorado's unprecedented price cap on Amgen's Enbrel
A US federal court has halted Colorado's attempt to impose a US$31,200 annual price cap on Amgen's arthritis drug Enbrel, ruling that the pharmaceutical company would likely suffer irreparable harm. The decision represents a significant blow to... -
News Protecting life-saving therapies: CPHI Online Podcast Series
The latest episode of the CPHI Podcast Series dives into a critical challenge facing the pharmaceutical industry: ensuring the integrity of temperature-sensitive medications and biologics through advanced predictive technology.
-
News 2026 Outsourcing Outlook Update - pharma at a crossroads
The pharmaceutical contract development and manufacturing organisation (CDMO) sector is experiencing unprecedented transformation, driven by evolving therapeutic complexities, geopolitical tensions, and the growing demand for specialised manufacturing ... -
News Roche maintains German investment commitment whilst rivals scale back
Pharmaceutical giant Roche has reaffirmed its commitment to investing in Germany, standing firm even as competitors Eli Lilly and Boehringer Ingelheim dramatically reduce their planned investments in response to controversial healthcare reforms.
-
News Women in Pharma: The History of CPHI Women in Japan
Our monthly Women in Pharma series highlights the influential lives and work of impactful women working across the pharmaceutical industry, and how the industry can work towards making the healthcare industry and workplace more equitable and inclusive. -
News EU drafts deal to end essential medicines shortage
European negotiators have agreed new legislation to tackle persistent shortages of essential medicines by prioritising supply security over price in public procurement and supporting domestic pharmaceutical manufacturing with strategic funding.
-
News Thermo Fisher Scientific offloads microbiology business to PE firm Astorg
The life sciences giant is divesting its global microbiology unit, which generated $645 million in revenue last year, to the pan-European private equity firm as part of an active portfolio management strategy. The transaction is expected to close in th... -
News The Shift: Why Sustainability is Moving to the Centre of CPHI Milan 2026
CPHI Online contributor David Roach takes a look at how conversations around sustainability in the pharmaceutical industry can and must be transformed into actionable deliveries, and what the inaugural CPHI Sustainability Summit means for the industry.